PERELMAN RONALD O
Known title: 10% OwnerCIK: 0001186472
Associated companies
Transaction History
| VTVT | ▼ Sell | Open Market | 87,000 | $100K | 12/20/2021 | View on chart |
| VTVT | ▼ Sell | Open Market | 87,000 | $100K | 12/20/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
VTVT Completes Phase 3 Cadisegliatin Trial Enrollment
vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.
VTVT Completes Phase 3 Cadisegliatin Trial Enrollment. vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.